Comparison of safety and immunogenicity between high-dose and low-dose quadrivalent influenza vaccines in children aged 6-35 months in China: A randomized, double-blind clinical study.
Xue Guo, Jingyu Li, Xufeng Dong et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, double-blind clinical study evaluated the safety and immunogenicity of high-dose versus low-dose quadrivalent influenza vaccines in 3,000 children aged 6-35 months in China. The high-dose vaccine (H-QIV) demonstrated over 11-fold increases in geometric mean titers against various influenza strains, with seroprotection rates exceeding 95%, indicating a stronger immune response compared to low-dose vaccines.
Key findings
- H-QIV showed >11-fold increases in GMTs against H1N1, H3N2, B/Yamagata, and B/Victoria strains.
- Seroprotection rates for H-QIV exceeded 95%, while seroconversion rates exceeded 89%.
- Both investigational vaccines met immunogenicity criteria for non-inferiority compared to the commercially available vaccine.
- All vaccines demonstrated comparable safety profiles within 6 months post-vaccination.
Why it matters
The findings suggest that high-dose influenza vaccines may offer enhanced protection for young children, a population at higher risk for severe influenza complications. Understanding the immunogenicity and safety profiles of these vaccines can inform vaccination strategies in pediatric care.